Evidence map›Paper›PMID 20555019›Full record

ArticleThe oncologist2010

Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.

Nakhle S Saba, Thomas J George, Brian C Boulmay

Abstract readCase Reports
In one paragraph

Article in The oncologist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nakhle S SabaSection of Hematology and Medical Oncology, Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Box T4M-2, New Orleans, Louisiana 70112, USA.
Thomas J George
Brian C Boulmay

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adjuvant interferon (IFN)-alpha remains the standard adjuvant therapy for intermediate and high-risk melanoma after definitive surgical resection. Data addressing the role and safety of adjuvant immunotherapy in HIV-infected patients with melanoma are lacking. We report on an HIV(+) patient who received IFN-alpha as adjuvant treatment for high-risk melanoma. To our knowledge, this is the first reported case of such an approach.

Indexed as

Adenocarcinoma, PapillaryAntineoplastic AgentsChemotherapy, AdjuvantDisease ProgressionHIV InfectionsHumansInterferon-alphaIodine CompoundsLymphatic MetastasisMaleMelanomaMiddle AgedNeck DissectionRadiographyRadiopharmaceuticalsSkin NeoplasmsAntineoplastic AgentsInterferon-alphaIodine CompoundsRadiopharmaceuticals

Identifiers

PMID20555019
PMCPMC3228003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.